Journal of Chemistry

Research Article

Sparfloxacin-Metal Complexes as Urease Inhibitors: Their Synthesis, Characterization, Antimicrobial, and Antienzymatic Evaluation

Table 5

(a) Inhibition zones (mm) against Bacillus subtilis. (b) Inhibition zones (mm) against Micrococcus luteus. (c) Inhibition zones (mm) against Staphylococcus aureus. (d) Inhibition zones (mm) against Streptococcus features. (e) Inhibition zones (mm) against Salmonella typhi. (f) Inhibition zones (mm) against Klebsiella pneumonia. (g) Inhibition zones (mm) against Proteus mirabilis. (h) Inhibition zones (mm) against Pseudomonas aeruginosa. (i) Inhibition zones (mm) against Escherichia coli. (j) Inhibition zones (mm) against Citrobacter species. (k) Inhibition zones (mm) against Shigella flexneri.

(a)


Complexes	Concentrations (μgmL⁻¹)
Complexes	5 (μgmL⁻¹)	10 (μgmL⁻¹)	20 (μgmL⁻¹)	40 (μgmL⁻¹)

SPFX	7.21 ± 0.2	15.3 ± 0.21	16.31 ± 0.04	17.28 ± 0.11
S12	8.09 ± 0.36** (−12.21)	9.29 ± 0.1** (39.28)	11.1 ± 0.08** (31.94)	14.05 ± 0.25** (18.69)
S13	8.84 ± 0.16** (−22.61)	11.01 ± 0.27** (28.04)	15.08 ± 0.18** (7.54)	18.32 ± 0.14** (−6.02)
S14	0 ± 0** (100)	0 ± 0** (100)	9.31 ± 0.25** (42.92)	10.28 ± 0.23** (40.51)
S15	6.97 ± 0.07** (3.33)	10.16 ± 0.2** (33.59)	12.21 ± 0.12** (25.14)	14.37 ± 0.06** (16.84)
ANOVA (df = 10, 22)	F-334.993	F-44.427	F-132.338	F-123.338

Mean ± S.D (percent zone of inhibition), **, *.

(b)


Complexes	Concentrations (μgmL⁻¹)
Complexes	5 (μgmL⁻¹)	10 (μgmL⁻¹)	20 (μgmL⁻¹)	40 (μgmL⁻¹)

SPFX	7.21 ± 0.2	15.3 ± 0.21	16.31 ± 0.04	17.28 ± 0.11
S12	8.09 ± 0.36** (−12.21)	9.29 ± 0.1** (39.28)	11.1 ± 0.08** (31.94)	14.05 ± 0.25** (18.69)
S13	8.84 ± 0.16** (−22.61)	11.01 ± 0.27** (28.04)	15.08 ± 0.18** (7.54)	18.32 ± 0.14** (−6.02)
S14	0 ± 0** (100)	0 ± 0** (100)	9.31 ± 0.25** (42.92)	10.28 ± 0.23** (40.51)
S15	6.97 ± 0.07** (3.33)	10.16 ± 0.2** (33.59)	12.21 ± 0.12** (25.14)	14.37 ± 0.06** (16.84)
ANOVA (df = 10, 22)	F-742.153	F-192.257	F-760.801	F-467.658

Mean ± S.D (percent zone of inhibition), **, *.

(c)


Complexes	Concentrations (μgmL⁻¹)
Complexes	5	10	20	40

SPFX	7.21 ± 0.2	15.3 ± 0.21	16.31 ± 0.04	17.28 ± 0.11
S12	8.09 ± 0.36** (−12.21)	9.29 ± 0.1** (39.28)	11.1 ± 0.08** (31.94)	14.05 ± 0.25** (18.69)
S13	8.84 ± 0.16** (−22.61)	11.01 ± 0.27** (28.04)	15.08 ± 0.18** (7.54)	18.32 ± 0.14** (−6.02)
S14	0 ± 0** (100)	0 ± 0** (100)	9.31 ± 0.25** (42.92)	10.28 ± 0.23** (40.51)
S15	6.97 ± 0.07** (3.33)	10.16 ± 0.2** (33.59)	12.21 ± 0.12** (25.14)	14.37 ± 0.06** (16.84)
ANOVA (df = 10, 22)	F-434.618	F-200.157	F-680.164	F-326.531

Mean ± S.D (percent zone of inhibition), **, *.

(d)


Complexes	Concentrations (μgmL⁻¹)
Complexes	5	10	20	40

SPFX	7.21 ± 0.2	15.3 ± 0.21	16.31 ± 0.04	17.28 ± 0.11
S12	8.09 ± 0.36** (−12.21)	9.29 ± 0.1** (39.28)	11.1 ± 0.08** (31.94)	14.05 ± 0.25** (18.69)
S13	8.84 ± 0.16** (−22.61)	11.01 ± 0.27** (28.04)	15.08 ± 0.18** (7.54)	18.32 ± 0.14** (−6.02)
S14	0 ± 0** (100)	0 ± 0** (100)	9.31 ± 0.25** (42.92)	10.28 ± 0.23** (40.51)
S15	6.97 ± 0.07** (3.33)	10.16 ± 0.2** (33.59)	12.21 ± 0.12** (25.14)	14.37 ± 0.06** (16.84)
ANOVA (df = 10, 22)	F-1304.177	F-1543.733	F-622.545	F-420.443

Mean ± S.D (percent zone of inhibition), **, *.

(e)


Complexes	Concentrations (μgmL⁻¹)
Complexes	5	10	20	40

SPFX	7.21 ± 0.2	15.3 ± 0.21	16.31 ± 0.04	17.28 ± 0.11
S12	8.09 ± 0.36** (−12.21)	9.29 ± 0.1** (39.28)	11.1 ± 0.08** (31.94)	14.05 ± 0.25** (18.69)
S13	8.84 ± 0.16** (−22.61)	11.01 ± 0.27** (28.04)	15.08 ± 0.18** (7.54)	18.32 ± 0.14** (−6.02)
S14	0 ± 0** (100)	0 ± 0** (100)	9.31 ± 0.25** (42.92)	10.28 ± 0.23** (40.51)
S15	6.97 ± 0.07** (3.33)	10.16 ± 0.2** (33.59)	12.21 ± 0.12** (25.14)	14.37 ± 0.06** (16.84)
ANOVA (df = 10, 22)	F-1304.177	F-1543.733	F-622.545	F-420.443

Mean ± S.D (percent zone of inhibition), **, *.

(f)


Complexes	Concentrations (μgmL⁻¹)
Complexes	5	10	20	40

SPFX	7.21 ± 0.2	15.3 ± 0.21	16.31 ± 0.04	17.28 ± 0.11
S12	8.09 ± 0.36** (−12.21)	9.29 ± 0.1** (39.28)	11.1 ± 0.08** (31.94)	14.05 ± 0.25** (18.69)
S13	8.84 ± 0.16** (−22.61)	11.01 ± 0.27** (28.04)	15.08 ± 0.18** (7.54)	18.32 ± 0.14** (−6.02)
S14	0 ± 0** (100)	0 ± 0** (100)	9.31 ± 0.25** (42.92)	10.28 ± 0.23** (40.51)
S15	6.97 ± 0.07** (3.33)	10.16 ± 0.2** (33.59)	12.21 ± 0.12** (25.14)	14.37 ± 0.06** (16.84)
ANOVA (df = 10, 22)	F-1304.177	F-1543.733	F-622.545	F-420.443

Mean ± S.D (percent zone of inhibition), **, *.

(g)


Complexes	Concentrations (μgmL⁻¹)
Complexes	5	10	20	40

SPFX	7.21 ± 0.2	15.3 ± 0.21	16.31 ± 0.04	17.28 ± 0.11
S12	8.09 ± 0.36** (−12.21)	9.29 ± 0.1** (39.28)	11.1 ± 0.08** (31.94)	14.05 ± 0.25** (18.69)
S13	8.84 ± 0.16** (−22.61)	11.01 ± 0.27** (28.04)	15.08 ± 0.18** (7.54)	18.32 ± 0.14** (−6.02)
S14	0 ± 0** (100)	0 ± 0** (100)	9.31 ± 0.25** (42.92)	10.28 ± 0.23** (40.51)
S15	6.97 ± 0.07** (3.33)	10.16 ± 0.2** (33.59)	12.21 ± 0.12** (25.14)	14.37 ± 0.06** (16.84)
ANOVA (df = 10, 22)	F-1304.177	F-1543.733	F-622.545	F-420.443

Mean ± S.D (percent zone of inhibition), **, *.

(h)


Complexes	Concentrations (μgmL⁻¹)
Complexes	5	10	20	40

SPFX	7.21 ± 0.2	15.3 ± 0.21	16.31 ± 0.04	17.28 ± 0.11
S12	8.09 ± 0.36** (−12.21)	9.29 ± 0.1** (39.28)	11.1 ± 0.08** (31.94)	14.05 ± 0.25** (18.69)
S13	8.84 ± 0.16** (−22.61)	11.01 ± 0.27** (28.04)	15.08 ± 0.18** (7.54)	18.32 ± 0.14** (−6.02)
S14	0 ± 0** (100)	0 ± 0** (100)	9.31 ± 0.25** (42.92)	10.28 ± 0.23** (40.51)
S15	6.97 ± 0.07** (3.33)	10.16 ± 0.2** (33.59)	12.21 ± 0.12** (25.14)	14.37 ± 0.06** (16.84)
ANOVA (df = 10, 22)	F-1304.177	F-1543.733	F-622.545	F-420.443

Mean ± S.D (percent zone of inhibition), **, *.

(i)


Complexes	Concentrations (μgmL⁻¹)
Complexes	5	10	20	40

SPFX	7.21 ± 0.2	15.3 ± 0.21	16.31 ± 0.04	17.28 ± 0.11
S12	8.09 ± 0.36** (−12.21)	9.29 ± 0.1** (39.28)	11.1 ± 0.08** (31.94)	14.05 ± 0.25** (18.69)
S13	8.84 ± 0.16** (−22.61)	11.01 ± 0.27** (28.04)	15.08 ± 0.18** (7.54)	18.32 ± 0.14** (−6.02)
S14	0 ± 0** (100)	0 ± 0** (100)	9.31 ± 0.25** (42.92)	10.28 ± 0.23** (40.51)
S15	6.97 ± 0.07** (3.33)	10.16 ± 0.2** (33.59)	12.21 ± 0.12** (25.14)	14.37 ± 0.06** (16.84)
ANOVA (df = 10, 22)	F-1304.177	F-1543.733	F-622.545	F-420.443

Mean ± S.D (percent zone of inhibition), **, *.

(j)


Complexes	Concentrations (μgmL⁻¹)
Complexes	5	10	20	40

SPFX	7.21 ± 0.2	15.3 ± 0.21	16.31 ± 0.04	17.28 ± 0.11
S12	8.09 ± 0.36** (−12.21)	9.29 ± 0.1** (39.28)	11.1 ± 0.08** (31.94)	14.05 ± 0.25** (18.69)
S13	8.84 ± 0.16** (−22.61)	11.01 ± 0.27** (28.04)	15.08 ± 0.18** (7.54)	18.32 ± 0.14** (−6.02)
S14	0 ± 0** (100)	0 ± 0** (100)	9.31 ± 0.25** (42.92)	10.28 ± 0.23** (40.51)
S15	6.97 ± 0.07** (3.33)	10.16 ± 0.2** (33.59)	12.21 ± 0.12** (25.14)	14.37 ± 0.06** (16.84)
ANOVA (df = 10, 22)	F-1304.177	F-1543.733	F-622.545	F-420.443

Mean ± S.D (percent zone of inhibition), **, *.

(k)


Complexes	Concentrations (μgmL⁻¹)
Complexes	5	10	20	40

SPFX	7.21 ± 0.2	15.3 ± 0.21	16.31 ± 0.04	17.28 ± 0.11
S12	8.09 ± 0.36** (−12.21)	9.29 ± 0.1** (39.28)	11.1 ± 0.08** (31.94)	14.05 ± 0.25** (18.69)
S13	8.84 ± 0.16** (−22.61)	11.01 ± 0.27** (28.04)	15.08 ± 0.18** (7.54)	18.32 ± 0.14** (−6.02)
S14	0 ± 0** (100)	0 ± 0** (100)	9.31 ± 0.25** (42.92)	10.28 ± 0.23** (40.51)
S15	6.97 ± 0.07** (3.33)	10.16 ± 0.2** (33.59)	12.21 ± 0.12** (25.14)	14.37 ± 0.06** (16.84)
ANOVA (df = 10, 22)	F-1304.177	F-1543.733	F-622.545	F-420.443

Mean ± S.D (percent zone of inhibition), **, *.